In an adjuvant-induced rat model of arthritis, IL-13 therapy reduced inflammation, vascularization, and bony destruction [56], while in an immune-complex-mediated arthritis mouse model, IL-13 overexpression diminished both chondrocyte death and MMP-mediated cartilage destruction, even though joint inflammation was enhanced [57]. This evidence concerns the gene IL13 and arthritic joint disease.